series-a
Stage
3
Investors
About
iFAST Diagnostics develops rapid antimicrobial susceptibility testing technology that provides results from Gram-negative positive blood cultures or bacterial isolates in under 3 hours to guide effective antibiotic prescription and combat antimicrobial resistance.
Explore iFAST Diagnostics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.